![]() | |
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | EGFR |
Clinical data | |
Trade names | Portrazza |
AHFS/Drugs.com | Multum Consumer Information |
License data |
|
Routes of administration | Intravenous infusion |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | ~14 days |
Identifiers | |
CAS Number | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
Chemical and physical data | |
Formula | C6436H9958N1702O2020S42 |
Molar mass | 144844.87 g·mol−1 |
![]() ![]() |
Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic, which is manufactured by Eli Lilly. It binds to the epidermal growth factor receptor (EGFR).[3] The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC).[4][5][6] It was counterproductive in non-squamous non-small-cell lung carcinoma.[6][7]
Monoclonal antibodies for tumors
| |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tumor |
| ||||||||||||
|
| |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Angiopoietin |
| ||||||||||
CNTF |
| ||||||||||
EGF (ErbB) |
| ||||||||||
FGF |
| ||||||||||
HGF (c-Met) |
| ||||||||||
IGF |
| ||||||||||
LNGF (p75NTR) |
| ||||||||||
PDGF |
| ||||||||||
RET (GFL) |
| ||||||||||
SCF (c-Kit) |
| ||||||||||
TGFβ |
| ||||||||||
Trk |
| ||||||||||
VEGF |
| ||||||||||
Others |
|
![]() | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
![]() | This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |